{
  "id": 1791327,
  "title": "Silo Pharma receives Canadian patent allowance for SPC-15 drug",
  "url": "https://urgent.news/2026/08/18/silo-pharma-receives-canadian-patent-allowance-for-spc-15-drug",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-08-18T20:20:29.000Z",
  "source": {
    "name": "Investing.com",
    "slug": "investing-com",
    "url": "https://www.investing.com/news/company-news/silo-pharma-receives-canadian-patent-allowance-for-spc15-drug-93CH-4866023"
  },
  "original_language": "en",
  "account": "Silo Pharma has received a patent allowance from Canada for their drug SPC-15, a nasal treatment aimed at treating stress-related psychiatric disorders. The patent application, titled \"Prophylactic Efficacy of Serotonin 4 Receptor Agonists Against Stress,\" covers methods of preventing or delaying stress-induced fear and depressive-like behavior using serotonin 4 receptor agonists. Silo Pharma has an exclusive license for the Canadian patent as part of a broader agreement with Columbia University to develop, manufacture, and sell SPC-15 worldwide. The company has also secured intellectual property rights in various international markets, including a recent European patent for the same invention. Silo Pharma is currently using the FDA's 505(b)(2) regulatory pathway for SPC-15 development and is a biopharmaceutical company focused on treatments for stress-induced psychiatric disorders, chronic pain, and central nervous system diseases.",
  "summary": null,
  "key_points": [
    "Silo Pharma granted Canadian patent for SPC-15 drug",
    "SPC-15 targets stress-related psychiatric disorders",
    "Silo Pharma exclusive license in Canada through Columbia University"
  ],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}